Compare TRVG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | PRTA |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | Germany | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.6M | 449.7M |
| IPO Year | 2015 | 2013 |
| Metric | TRVG | PRTA |
|---|---|---|
| Price | $5.87 | $9.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $3.95 | ★ $19.00 |
| AVG Volume (30 Days) | 163.9K | ★ 333.2K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | $15.59 | $1,111.38 |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | ★ $16.98 | $37.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.59 | $7.73 |
| 52 Week High | $6.49 | $11.80 |
| Indicator | TRVG | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.87 | 57.94 |
| Support Level | $2.76 | $8.10 |
| Resistance Level | N/A | $10.11 |
| Average True Range (ATR) | 0.42 | 0.36 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 69.27 | 75.43 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.